Mycoplasma Fementans Incognitus Frequencies Version 1.0 Previous item Science That Works... Next item Pseudoscience: Half of the...

Mycoplasma Fementans Incognitus Frequencies Version 1.0

United States Patent 5,242,820
Lo September 7, 1993

Pathogenic Mycoplasma (Mycoplasma Fermentans Incognitus)

Abstract
The invention relates to a novel pathogenic mycoplasma isolated from patients with Acquired Immune Deficiency Syndrome (AIDS) and its use in detecting antibodies in sera of AIDS patients, patients with AIDS-related complex (ARC) or patients dying of diseases and symptoms resembling AIDS diseases. The invention further relates to specific DNA sequences, antibodies against the pathogenic mycoplasma, and their use in detecting DNA or antigens of the pathogenic mycoplasma or other genetically and serologically closely related mycoplasmas in infected tissue of patients with AIDS or ARC or patients dying of symptoms resembling AIDS diseases. The invention still further relates to a variety of different forms of vaccine against mycoplasma infection in humans and/or animals.


Inventors: Lo; Shyh-Ching (Potomac, MD)
Assignee: American Registry of Pathology (Washington, DC)
Family ID: 27401851
Appl. No.: 07/710,361
Filed: June 6, 1991

Related U.S. Patent Documents

Application Number Filing Date Patent Number Issue Date
265920 Nov 2, 1988
875535 Jun 18, 1986

Other References

Marquart et al (1985) Mycoplasma-Like Structures . . . Eur J Clin Microbiol 4(1):73-74. .
Lo et al (1989) A Novel Virus-like Infectious Agent . . . Am J Trop Med Hyg 40(2):213-226. .
Lo et al (1989) Identification of M Incognitus . . . Am. J. Trop-Med. Hyg 41(5):601-616. .
Lo et al (1989) Association of the Virus-like Agent . . . Am J Trop Med Hyg 41(3):364-376. .
Lo et al (1989) Fatal Infection of Silvered Leaf Monkeys . . . Am. T Trop Med Hyg 40(4):399-409. .
Lo et al (1989) Virus-like Infectious Agent . . . Am J Trop Med Hyg 41(5):586-600. .
Marquart et al (Feb. 1985) Abstract Only Eur J Clin Microbiol 4(1):73-74. .
Hu et al (1990) Gene 93:67-72..

Primary Examiner: Nucker; Christine M.
Assistant Examiner: Preston; D. R.
Attorney, Agent or Firm: Venable, Baetjer, Howard & Civiletti


Government Interests
The invention described herein was made in the course of work under a grant or award from the United States Department of the Army.


Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part of U.S. patent application Ser. No. 265,920, filed Nov. 2, 1988, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 875,535, filed Jun. 18, 1986, now abandoned.


Claims
What is claimed is:
1. A biologically pure mycoplasma isolated from tissues of patients with AIDS comprising the mycoplasma produced by the cell line ATCC No. CRL 9127.
2. A biologically pure mycoplasma having the identifying characteristics of M. fermentans incognitus, ATCC 53949.


Description
BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a novel strain of mycoplasma isolated from a patient with AIDS. The mycoplasma is closely related to a species of human mycoplasma, M. fermentans. Upon characterization of this mycoplasma, it may be classified as a unique strain within the species M. fermentans incognitus. This novel strain of nycoplasma is referred to hereinafter as the incognitus strain or M. fermentans incognitus.

The invention also relates to use of the mycoplasma M. fermentans incognitus as well as all strains of M. fermentans in detecting specific antibodies in sera of patients with AIDS or an acute fulminant systemic disease and/or animals and its use as a vaccine against infection by the mycoplasma. The invention further relates to incognitus strain-specific antibodies and cross-reactive which later break up into individual cells that are capable of passing through membrane filters of pore size 0.45 .mu.m or even 0.22 .mu.m.


Those with Lyme disease may already be aware of this coinfection. It appears to be circulating with the 2017 flu causing extended periods of serious illness. Frequencies are available to subscribers.

Add Your Comment

Your email address will not be published. Required fields are marked *